Introduction
Thyroid carcinoma, accounting for nearly 1% of all the cancers, is the most common malignancy in the endocrine organs. 1 Traditionally, thyroid carcinomas are classified into papillary thyroid cancer (PTC), follicular thyroid cancer, medullary thyroid cancer, poorly differentiated thyroid cancer and anaplastic thyroid cancer, based on histopathology. 2 In China, it has been reported that 90 per 100,000 people were submit your manuscript | www.dovepress.com
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Pan et al diagnosed with thyroid cancer and 6.8 people died among these patients. 3 In USA, it has been estimated that 1,980 people died of the disease in 2016 4 and there will be 64,300 new patients of thyroid cancer. The diagnosis of thyroid cancer is often based on magnetic resonance imaging, ultrasound, computed tomography, fine needle aspiration and radionuclide imaging. Although various methods are well applied in clinics, patients often have poor outcome. Reports have shown that the patients' age when being diagnosed, sex, tumor size, lymph node, distant metastases and pathologic differentiation of the cancer are the risk factors of prognosis in thyroid cancer. [5] [6] [7] [8] However, no studies showed the markers had prognostic value in thyroid cancer. Cell proliferative activity is an important factor in cancer biologic behavior. Ki-67, considered as a nuclear antigen, is expressed in all cell nuclei, except those in the G0 phase. Further, MIB-1 acts as a monoclonal antibody which increases against Ki-67. In recent years, Ki-67 has been studied in many cancers, including cervical cancer, 9 lung cancer, 10 breast cancer 11 and thyroid cancer. 12 It has been reported that Ki-67 is an independent prognostic factor in thyroid cancer patients. 13 A study predicted that patients with Ki-67 labeling index (LI) .3% would show a worse causespecific survival than those with Ki-67 LI ,3%. 12 However, Gnemmi et al 14 reported that Ki-67 LI ($4%) is an independent factor and predictor of cause-specific survival.
Though many studies have demonstrated Ki-67/MIB-1 is expressed in thyroid cancer, there is no systematic literature assessing the relationship between Ki-67/MIB-1 expression and clinical factors in thyroid cancer patients. So, the significance of Ki-67/MIB-1 for prognostication of thyroid cancer remains uncertain. Thus, a literature-based meta-analysis study was performed to evaluate the diagnostic and prognostic values of Ki-67/MIB-1 in thyroid cancer.
Materials and methods
Studies selection
Studies were selected to demonstrate the diagnostic and prognostic values of Ki-67/MIB-1 for thyroid cancer. Electronic literatures were searched in PubMed, EBSCO, EMBASE, ISI Web of Science, WanFang, China National Knowledge Infrastructure and Chinese VIP databases from April 1, 1989 to July 31, 2016. The following keywords were used to identify the related publications: "thyroid cancer", "Ki-67", "MIB-1", "proliferative marker", "proliferative index", "diagnosis", "prognostic", "survival". The eligible studies were selected in accordance with the following criteria: 1) studies should be published in full assays; 2) the goal of the publication was to illustrate the clinical significance of Ki-67/MIB-1 in primary thyroid cancer; 3) sufficient data were used to determine the connection between Ki-67/MIB-1 and clinicopathologic parameters; 4) when the same patient cohort was reported in different publications, only the most complete and recent study was selected in the meta-analysis.
Also, we screened the references from the reviews and identified articles.
Data extraction and assessment of study quality
Three authors (Deng-hua Pan, Dong-yue Wen and Yi-huan Luo) read the studies carefully and independently. The information of the publications was collected from each study: first author's name, publication date, the number of patients, patient age, country, follow-up time, antibody of testing Ki-67/MIB-1, the method of detecting Ki-67/MIB-1 expression and threshold used for assessing Ki-67/MIB-1 expression positively. True positive, true negative, false positive and false negative were extracted to construct a diagnostic contingency table. Disease-free survival (DFS) or mortality or distant recurrences-free survival was used to measure the effect of Ki-67/MIB-1 expression on survival in thyroid cancer patients. The following clinical parameters were extracted to evaluate the connection between Ki-67/ MIB-1 and thyroid cancer aggressiveness: age, tumor size, lymph node metastasis, metastasis status, extrathyroid extension, tumor node metastasis stage. Minimal size of patients and minimal follow-up time are not defined in this meta-analysis. Studies that met the following criteria were excluded: 1) reviews, conference papers, case reports, expertise public opinion, letters, zoopery were not included; 2) studies without sufficient information to calculate the impact of diagnosis, survival and prognosis of Ki-67/MIB-1 in primary thyroid cancer were excluded; 3) studies with duplicated data from similar or the same population were excluded. QUADAS-2 was used to assess the quality of the studies for diagnosis. 15 Newcastle-Ottawa scale (NOS) was used to assess the quality of the studies for prognosis. 16 The study with NOS scores $6 was identified as a high-quality study and the study with NOS scores ,6 was considered as a low-quality study.
Statistical methods
According to the cut-off values, Ki-67/MIB-1 expression was divided into positive and negative groups. The pooled OncoTargets and Therapy 2017:10 submit your manuscript | www.dovepress.com
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Ki-67/MiB-1 expression in thyroid cancer sensitivity and specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR−), diagnostic odds ratio (DOR) and the area under the symmetric receiver operating characteristic curve were used to measure the diagnosis of Ki-67/MIB-1 in thyroid cancer. The odds ratio (OR) and 95% confidence intervals (CIs) were used to estimate the relationship between Ki-67/MIB-1 and clinicopathologic parameters in thyroid cancer patients. When the OR was .1, it indicated that high Ki-67/MIB-1 was a risk factor in thyroid cancer. Hazard ratio (HR) and 95% CI were calculated to measure the effect of Ki-67/MIB-1 on prognosis. Also, when the HR was .1, it indicated that high level of Ki-67/MIB-1 was related to worse survival in thyroid cancer patients.
Further, Cochran's Q-test was performed to measure heterogeneity. Also, I
2 was calculated to assess the inconsistency of the studies. When I 2 was over 50% or chi-squared P-value was .0.1, fixed-effect meta-analysis was performed; otherwise, random-effect meta-analysis was used when there was less or no heterogeneity (when I 2 was less than 50% or chi-squared P-value was ,0.1). MetaDiSc was used to measure the diagnosis of Ki-67/MIB-1 in thyroid cancer. STATA12.0 was used to calculate the progression and prognosis of Ki-67/MIB-1 in thyroid cancer. The potential publication bias was investigated through funnel plot and by computation of Begg's test. When the P-value was ,0.05, it was considered significant.
Results
Description of studies
The flow chart of search process is presented in Figure 1 . One thousand one hundred and sixty-two relevant studies were identified. After reviewing the abstracts and full text, only 51 studies 1, 12, 14, were found to be eligible and were included in the meta-analysis. The characteristics of these articles are summarized in Tables 1-3 . Table 1 gives the main information of the studies included in diagnosis. Thirty-seven studies Notes: A: representative of the exposed cohort; B: selection of the nonexposed cohort; C: ascertainment of exposure; D: demonstration that outcome of interest was not present at the start of study; e: comparability of cohorts on the basis of the design or analysis; F: assessment of outcome; G: adequacy of follow-up for outcomes to occur ($2 years or outcomes occurred in all patients); H: adequacy of follow-up of cohorts (follow-up rate $75%). Abbreviation: NOS, Newcastle-Ottawa scale.
detecting the diagnostic value of Ki-67/MIB-1 in thyroid cancer were included in our analysis, including 4,818 samples (2,601 cases and 2,217 controls). The quality assessment of the included studies in diagnosis is shown in Figure 2 . The risks of bias in "index test" and "reference standard" were unclear in this meta-analysis. Table 2 shows the correlation between clinicopathologic parameters and Ki-67/MIB-1, including 4,375 samples (1,317 cases and 3,058 controls). As shown in Table 3 , a total of 10 studies reporting the relation between Ki-67/MIB-1 and thyroid cancer patient survival were included, of which three studies had data on DFS, seven on mortality and only one on distant recurrences-free survival (DRFS). The studies included in survival analysis had 1,083 samples. The age of patients ranged from 45 to 64.8 years, and the median follow-up time ranged from 68 months to 20 years. Immunohistochemistry (IHC) was used to detect the expression of Ki-67/MIB-1 in all the included studies. The cut-off value ranged from 1% to 10%. The quality assessment of the studies included in prognosis is shown in Table 4 .
effect of Ki-67/MiB-1 on diagnosis
Due to heterogeneity, random-effect model was used to calculate the overall performance of Ki-67/MIB-1 in thyroid tissues in diagnosing thyroid cancer. Ki-67/MIB-1 was found to be a valuable diagnostic factor for thyroid cancer. The pooled sensitivity was 0.61 (95% CI: 0.59-0.63; Figure 3A ) and specificity was 0.75 (95% CI: 0.74-0.77; Figure 3B ). The pooled LR+ was 3.19 (95% CI: 2.30-4.42; Figure 3C ) and the pooled LR− was 0.43 (95% CI: 0.35-0.54; Figure 3D ). The pooled DOR of Ki-67/MIB-1 was 8.54 (95% CI: 5.03-14.49; Figure 4 ). The area under the symmetric receiver operating characteristic curve was 0.804 (standard error =0.031; Figure 5 ). For Ki-67/MIB-1, the summary indexes of 37 studies are displayed in forest plots. High heterogeneity was found in sensitivity (I 2.48-9.17), respectively (Table S1 ).
Associations of Ki-67/MiB-1 with clinicopathologic parameters Table 2 shows the main results of the effects value of Ki-67/ MIB-1 on clinicopathologic parameters in thyroid cancer Figure 7 ). The meta-analysis showed overexpression of Ki-67/MIB-1 had effect on mortality (HR =3.56, 95% CI: 1.17-10.83, P=0.025) in eight studies, with heterogeneity (I 2 =73.5%, P,0.001; Figure 8 Figure 6A ). The level of Ki-67/MIB-1 was higher in large tumor size (.4 cm) than in small-sized tumor (,4 cm; pooled OR =1.86, 95% CI: 1.17-2.96, P=0.008; I 2 =2.00%, P=0.395; Figure 6B ). Overall, 15 studies had data to estimate the relationship between Ki-67/MIB-1 and lymph node metastasis. The pooled OR estimated from 15 studies indicated that Ki-67/MIB-1 was lower in negative lymph node metastasis than in positive lymph node metastasis (pooled OR =2.49, 95% CI: 1.42-4.39, P=0.002; I 2 =50.20%, P=0.014; Figure 6C) . Also, the association between Ki-67/ MIB-1 and metastasis status was calculated and the combined OR was 6.96 (95% CI: 2.46-19.69, P,0.001; Figure 6D ). The combined OR for tumor node metastasis stage was 6.56 (95% CI: 3.80-11.33, P,0.001; I 2 =0.00%, P=0.960), suggesting that overexpression of Ki-67/MIB-1 was significantly correlated with advanced stage ( Figure 6E ). In addition, four studies provided insufficient information to estimate the effect of extrathyroid extension. The pooled OR was 1.91 (95% CI: 1.27-2.87, P=0.002; Figure 6F ).
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Ki-67/MiB-1 expression in thyroid cancer no significant relationship was observed between PTC and mortality (HR =1.47, 95% CI: 2.23-5.18; Table S2 ).
Publication bias
The Begg's test and funnel plot showed that there was no evidence of publication bias present among all the analyses in our meta-analysis (all P.0.05; Figures 9 and 10 ).
Discussion
Cell proliferative activity is regarded as an important factor for evaluating the biologic behavior of cancer cells. It is a key process in the development of tumors when the balance between cell death and proliferation is destroyed. We used IHC to detect cell cycle-specific antigens and this method can assess the proliferative activity of cells. Ki-67/MIB-1 is the most widely used marker for assessing the proliferative capacity of tumor cells. Increased expression of Ki-67/ MIB-1 has been linked to increased invasiveness in many cancers. 10, [65] [66] [67] Many meta-analyses have shown that high expression of Ki-67/MIB-1 contributed to poor survival in many tumors. [68] [69] [70] [71] [72] However, there is no consensus on the association between high level of Ki-67/MIB-1 and thyroid cancer at present. Meta-analysis is a systematical method applied widely to evaluate the prognostic indicators in different trials. Thus, in this meta-analysis, we explored the diagnosis and prognosis of Ki-67/MIB-1 expression in thyroid cancer.
In our study, we found the valuable predicting effect of Ki-67/MIB-1 for the diagnosis of thyroid cancer with a high accuracy for Chinese. In clinical practice, detecting Ki-67/ MIB-1 expression may contribute to diagnosing thyroid cancer when combined with clinical symptoms, laboratory examinations and other radiologic imaging. Our analysis demonstrated that patients with overexpression of Ki-67/ MIB-1 seemed to have a poor survival in thyroid cancer. Also, Ki-67/MIB-1 was found to be associated with tumor size, lymph node metastasis, metastasis status, extrathyroid extension and other clinicopathologic parameters. However, the mechanism of Ki-67/MIB-1 in thyroid cancer is still unclear. Ki-67/MIB-1 as a cellular marker has a positive effect on cell proliferation. Ki-67/MIB-1 expression detected by IHC can evaluate tumor cell proliferation. A previous study confirmed that Sp1 plays an important role in regulation of Ki-67/MIB-1 gene expression. 73 Another study pointed out that E2F2 transcription factor was positively correlated with Ki-67/MIB-1 expression in human glioblastoma 
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Ki-67/MiB-1 expression in thyroid cancer which contributed to the heterogeneity. Also, various cut-off values were used to define thyroid cancer with Ki-67/MIB-1 positive expression by different investigators, which potentially contributed to the heterogeneity. So, it is difficult to apply a standard critical value in clinical practice. Spyratos et al 76 found that few tumors with low proliferation rate were under misclassification when the cut-off value of Ki-67/MIB-1 was 10%, and it is acceptable to identify a highly proliferative tumor with a Ki-67/MIB-1 cut-off value of 25%. In this metaanalysis, the cut-off values of Ki-67/MIB-1 ranged from 0.5% pathway regulates E2F1-3 factors which could control cellular proliferation. 75 In this meta-analysis, heterogeneity existed among the studies. Heterogeneity was still a potential problem which affected the meta-analysis results, though random-effect models were used to analyze the data. Meanwhile, in order to reduce heterogeneity, only the studies with the method of IHC to detect Ki-67/MIB-1 were included in this metaanalysis. However, evaluation standards, study location, number of patients, sex and age of patients were different, to 25%. Therefore, different Ki-67/MIB-1 cut-offs may cause heterogeneity. Higher sensitivity, specificity and DOR were found in patients with cut-off value .10% by diagnostic subgroup analysis. Furthermore, those patients may have worse mortality. Given the small size of studies included in mortality analysis, further research with larger sample size would be needed to explore the impact of KI-67/MIB-1 on mortality. Besides, HRs were extracted from survival curves 
SE of: logHR LogHR
or calculated from data which might be less than another variance. Most of the studies included in diagnosis were from China; however, most of the studies related to DFS and mortality were from outside of China. We found that Ki-67/MIB-1 had a diagnostic value in Chinese. However, we did not have enough data to calculate the relationship between Ki-67/MIB-1 and mortality for Chinese. So, regional variation may become a score of heterogeneity. Besides, due to several types of thyroid cancer dealt with in the same study, we conducted subgroup analysis in this metaanalysis. Ki-67/MIB-1 had diagnostic effect on different thyroid cancer types. We did not find significant association between Ki-67/MIB-1 and different thyroid cancer types. Despite the above limitations, the current meta-analysis proves the associations between high Ki-67/MIB-1 and tumor deterioration, poor DFS and increased mortality in patients with thyroid cancer. In conclusion, we showed that high expression of Ki-67/MIB-1 was significantly connected with tumor size, lymph metastasis, metastasis status, extrathyroid extension and poor prognosis of thyroid cancer in this study.
Conclusion
Our meta-analysis shows that Ki-67/MIB-1 may be a biomarker for clinical deterioration in Chinese and has an effect on prognosis in thyroid cancer among non-Chinese. Therefore, detection of Ki-67/MIB-1 in the clinic will be beneficial to the treatment and prognostic assessment for thyroid cancer patients. However, well-designed prospective studies are necessary to further confirm our results.
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